TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
TG Therapeutics, Inc. (TGTX) announced that its CEO, Michael S. Weiss, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 9:45 AM ET. The event aims to highlight the company’s advancements in novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics has received FDA accelerated approval for UKONIQ®, targeting specific lymphoma patients, and is progressing with three Phase 3 programs and several Phase 1 investigational medicines. A live webcast will be accessible on their website.
- None.
- None.
Presentation scheduled for Monday January 10, 2022 at 9:45 AM ET
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday January 10, 2022 at 9:45 AM ET.
A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG’s website following the event.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ® (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has three programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.
UKONIQ® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is TG Therapeutics presenting at the J.P. Morgan Healthcare Conference?
Who is the CEO of TG Therapeutics?
What is UKONIQ® approved for?
What is the focus of TG Therapeutics?
How can I access the webcast of the presentation?
